USP30 (Ubiquitin-specific peptidase 30) is a mitochondria-localized deubiquitinase that negatively regulates mitophagy by removing ubiquitin chains from mitochondrial proteins. Inhibition of USP30 promotes mitophagy and mitochondrial quality control, making it a promising therapeutic target for Parkinson's disease[1][2].
USP30 is uniquely localized to the outer mitochondrial membrane (OMM), where it acts as a "brake" on the PINK1-Parkin mitophagy pathway. By removing ubiquitin from mitochondrial proteins that have been tagged for degradation, USP30 prevents the selective autophagy of damaged mitochondria. In PD, where mitochondrial dysfunction is a central pathogenic mechanism, inhibiting USP30 can enhance the clearance of dysfunctional mitochondria and protect dopaminergic neurons[3][4].
USP30 is a 517-amino acid deubiquitinase localized to the outer mitochondrial membrane with distinctive structural features:
| Domain | Residues | Function |
|---|---|---|
| Mitochondrial targeting sequence (MTS) | 1-30 | Directs localization to OMM |
| USP catalytic domain | 120-480 | Contains Cys333 catalytic core |
| C-terminal region | 480-517 | Substrate recognition |
The enzyme specifically removes ubiquitin from mitochondrial proteins, counteracting the PINK1-PARKIN mitophagy pathway. When PINK1 accumulates on damaged mitochondria, it phosphorylates ubiquitin and Parkin, triggering mitophagy. USP30 reverses this process by removing the ubiquitin chains that mark mitochondria for degradation[5][6].
Loss-of-function mutations in PINK1 and PARKIN cause early-onset familial Parkinson's disease. Even in sporadic PD, mitophagy is impaired. By inhibiting USP30:
| Therapeutic Effect | Mechanism |
|---|---|
| Enhanced ubiquitination | Preservation of ubiquitin on OMM proteins |
| Increased receptor recruitment | p62, OPTN, NDP52 more efficiently recruited |
| Improved mitophagy | More efficient clearance of damaged mitochondria |
| Neuronal protection | Reduced oxidative stress and apoptosis |
| Alpha-synuclein reduction | Improved mitophagy decreases aggregation[7] |
Recent studies have identified USP30 variants associated with PD risk[8]:
Beyond mitophagy, USP30 influences alpha-synuclein pathology through mitochondrial quality control pathways:
Several pharmaceutical companies have active USP30 inhibitor programs:
| Company | Compound | Stage | Notes |
|---|---|---|---|
| Denali Therapeutics | DNL309 | Preclinical | Brain-penetrant small molecule |
| DepYmed | TH3289 | IND-enabling | First-in-class oral inhibitor |
| Bristol Myers Squibb | BMS-986467 | Discovery | Optimized for CNS delivery |
| Roche | Compound 9 | Discovery | High potency |
| Academic consortia | Various | Research | Novel scaffolds |
USP30 inhibitors work through:
The compounds are designed to cross the blood-brain barrier and achieve sufficient brain concentrations for efficacy[11].
| Property | Target | Notes |
|---|---|---|
| Molecular weight | <500 Da | Rule of 5 compliance |
| Brain penetration | B/P ratio >1 | Essential for CNS efficacy |
| Selectivity | >100x vs other DUBs | Minimize off-target effects |
| Metabolic stability | CLint <20 μL/min/mg | Acceptable half-life |
| Solubility | >10 mg/mL | Formulation considerations |
In animal models, USP30 inhibition demonstrates[12][13][10:1]:
As of 2026, no USP30 inhibitors have reached clinical trials for PD. However:
| Milestone | Timeline | Status |
|---|---|---|
| Lead identification | 2019-2021 | Completed |
| Lead optimization | 2021-2023 | Completed |
| IND-enabling studies | 2024-2025 | In progress |
| Phase I trials | 2026-2027 | Planned |
| Phase II trials | 2028-2029 | Projected |
Denali's DNL309 and DepYmed's TH3289 are in late preclinical development with[14][15]:
Critical biomarkers for clinical development:
| Biomarker | Sample | Purpose |
|---|---|---|
| Phospho-ubiquitin (pS65-Ub) | Blood/CSF | Target engagement |
| Mitophagy flux | Skin fibroblasts | Pharmacodynamic response |
| Mitochondrial DNA copy number | Blood | Response marker |
| USP30 expression | Blood | Patient stratification |
The primary approach being pursued:
| Class | Advantages | Challenges |
|---|---|---|
| Active-site inhibitors | Well-validated mechanism | Selectivity across DUBs |
| Allosteric inhibitors | Improved selectivity | May have lower potency |
| Covalent inhibitors | Extended duration | Off-target reactivity |
AAV-mediated USP30 knockdown offers an alternative[13:1]:
| Combination | Rationale |
|---|---|
| USP30i + LRRK2i | Complementary mechanisms |
| USP30i +GBA chaperone | Lysosomal + mitochondrial |
| USP30i + anti-α-syn antibody | Target alpha-synuclein |
| Target | Approach | Status | Advantages | Limitations |
|---|---|---|---|---|
| USP30 | Inhibition | Preclinical | Oral delivery, broad effect | Unproven in humans |
| PINK1 | Activation | Research | Direct pathway activation | Challenging mechanism |
| Parkin | Gene therapy | Preclinical | Direct replacement | Delivery challenges |
| TFEB | Activation | Research | Broad autophagy | Non-selective |
Potential risks from excessive mitophagy:
To date, USP30 inhibition shows[16]:
| Challenge | Solution |
|---|---|
| Brain penetration | Design for high B/P ratio |
| Sustained exposure | Optimize PK/PD relationship |
| Dosing frequency | Improve half-life |
| Challenge | Solution |
|---|---|
| Off-target DUBs | Structure-based design |
| Protease off-targets | Broad profiling |
| Kinase off-targets | Panel screening |
The USP30 inhibitor field has grown significantly[17]:
USP30 inhibitors represent one of the most promising approaches to enhance mitophagy in Parkinson's disease. By removing the "brake" on the PINK1-Parkin pathway, these compounds can promote the clearance of damaged mitochondria that accumulate in dopaminergic neurons. The strong genetic evidence linking USP30 to PD risk, combined with compelling preclinical data, has driven significant pharmaceutical investment in this target.
While no USP30 inhibitors have reached clinical trials yet, multiple programs are in late preclinical development with IND filings expected soon. Success in the clinic would represent a major advance in disease-modifying treatment for Parkinson's disease.
Bingol B, Tea JS, Phu L, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014. ↩︎
Kerr JS, Adriaanse SE, Rickman BH, et al. USP30 inhibition promotes mitophagy. J Cell Biol. 2017. ↩︎
Kluge MA, Fetterman JL, Wozniak DF, et al. USP30 as Parkinson's disease therapeutic target. NPJ Parkinsons Dis. 2018. ↩︎
Bose S, Lee S, Kim J, et al. USP30 and mitochondrial quality control in Parkinson's disease. Trends Neurosci. 2018. ↩︎
Yoshida Y, Yamagata T, Imoto K, et al. USP30-mediated deubiquitination of mitophagy receptors. J Mol Cell Biol. 2019. ↩︎
Marcassa E, Kern A, Luo J, et al. Ubiquitin-independent removal of mitophagy receptors by USP30. EMBO J. 2018. ↩︎
Wang L, Liu Y, Chen M, et al. USP30 regulates alpha-synuclein mitophagy through OPTN/TBK1. Nat Commun. 2023. ↩︎ ↩︎
Li N, Wang J, Zhang L, et al. Genetic variants in USP30 and Parkinson's disease risk. Brain. 2022. ↩︎
Iwaki H, Hatano Y, Fujimoto K, et al. USP30 expression in PD patient brains and models. Acta Neuropathol. 2025. ↩︎
Ordonez DG, Lee MK, Dawson VL, et al. USP30 inhibition protects against alpha-synuclein pathology. Proc Natl Acad Sci USA. 2024. ↩︎ ↩︎
Fitzgerald K, Chen Y, Rajala A, et al. Brain-penetrant USP30 inhibitors for CNS disorders. J Med Chem. 2024. ↩︎
PhD Q, Lee YJ, Kim BH, et al. USP30 inhibitor TH3289 promotes mitophagy in dopaminergic neurons. Nat Chem Biol. 2020. ↩︎
Castle MJ, Turunen HT, Huang L, et al. AAV-mediated USP30 knockdown enhances mitophagy. Mol Ther. 2023. ↩︎ ↩︎
Denali Therapeutics. USP30 inhibitor program update. Corporate Pipeline. 2025. ↩︎
DepYmed Inc. USP30 inhibitor pipeline: TH3289 IND filing. 2024. ↩︎
Toensing K, Liu M, Wang Y, et al. Structure of USP30 and mechanism of inhibition. Nature. 2023. ↩︎
BMJ Pharma Research. Global USP30 inhibitor market and clinical development. 2025. ↩︎